Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohnʼs disease and analysis of the IL17F p.His161Arg polymorphism in IBD

Julia Seiderer(Ludwig-Maximilians-Universität München), Ira Elben(Ludwig-Maximilians-Universität München), Julia Diegelmann(Ludwig-Maximilians-Universität München), Jürgen Glas(Ludwig-Maximilians-Universität München), Johannes Stallhofer(Ludwig-Maximilians-Universität München), Cornelia Tillack(Ludwig-Maximilians-Universität München), Simone Pfennig(Ludwig-Maximilians-Universität München), Matthias Jürgens(Ludwig-Maximilians-Universität München), Silke Schmechel(Ludwig-Maximilians-Universität München), Astrid Konrad(Ludwig-Maximilians-Universität München), Burkhard Göke(Ludwig-Maximilians-Universität München), Thomas Ochsenkühn(Ludwig-Maximilians-Universität München), Bertram Müller‐Myhsok(Max Planck Institute of Psychiatry), Peter Lohse(Ludwig-Maximilians-Universität München), Stephan Brand(Ludwig-Maximilians-Universität München)
Inflammatory Bowel Diseases
December 19, 2007
10.1002/ibd.20339
Cited by 325Open Access
Full Text

Abstract

Background: Interleukin (IL)-17F, produced in IL-23R-expressing Th17 cells, is a novel member of the IL-17 cytokine family. Given the association of IL23R with inflammatory bowel disease (IBD), we characterized the role of IL-17F in IBD including its intestinal gene expression and the effect of the IL17F p.His161Arg polymorphism on disease susceptibility and phenotype of Crohn's disease (CD) and ulcerative colitis (UC). In addition, we analyzed the IL17F p.His161Arg polymorphism for potential epistasis with IL23R and NOD2/CARD15 variants.

Related Papers

No related papers found

Powered by citation graph analysis